Blood Tests in Peptide Research and Treatment
How to interpret laboratory monitoring by indication and product, including IGF-1 and glucose, without universal thresholds for investigational peptides.
Laboratory tests are useful when a specific medicine, condition, and clinical question are defined. There is no single baseline panel, IGF-1 cutoff, or testing schedule that validates every peptide regimen. A normal result cannot establish that an investigational product is safe or effective.
IGF-1 and growth hormone agents
IGF-1 varies with age and the laboratory method. The report's reference interval and, when relevant, age-adjusted standard-deviation score (SDS) are more informative than a fixed number such as “350–400 ng/mL.” Clinical findings matter alongside the measurement.
The FDA label for EGRIFTA WR (tesamorelin) describes IGF-1 monitoring for that approved product and indication and asks clinicians to consider stopping for persistent elevations, for example above 3 SDS. This is not a universal rule for CJC-1295, ipamorelin, MK-677, or other agents. Their safety and monitoring have not been established by borrowing the tesamorelin label.
Glucose and other tests
A clinician may use glucose or HbA1c to assess diabetes risk or the effects of a medicine known to alter glucose handling. The appropriate interval depends on the patient's baseline status, indication, product label, symptoms, and concurrent medicines. The tesamorelin label warns about glucose intolerance and diabetes; approved incretin products have different indications and warnings. Liver, kidney, blood-count, or hormone tests should likewise address a defined clinical question, not be ordered as a universal “peptide stack panel.”
Reading results responsibly
- Compare results with the laboratory's own interval and the person's prior values.
- Consider symptoms, age, medical history, assay differences, and medicines.
- Use the monitoring instructions for a specific approved product where available.
- Do not treat an expected biomarker change as proof of benefit.
- Seek clinical assessment for a concerning result or symptom rather than adjusting an investigational regimen from an online threshold.
For the evidence behind growth hormone secretagogue combinations, see Growth Hormone Secretagogues: Evidence and Safety.
References
Peptide Bioavailability: How to Read PK and Formulation Claims
Learn how to interpret peptide bioavailability, AUC, Cmax, formulation studies, and oral-delivery claims without mistaking exposure for efficacy.
Peptide Bonds: Structure, Formation, and Hydrolysis
Learn what a peptide bond is, how ribosomes and laboratories form it, why it is planar, how proteases cleave it, and what bond claims prove.